<unk>  (Epanova) is a formerly-marketed yet still FDA approved prescription medication–since taken off market by the manufacturer–used alongside a low fat and low cholesterol diet that lowers high triglyceride (fat) levels in adults with very high levels. This was the third class of fish oil-based drug, after omega-3<unk> ethyl esters (Lovaza and Omtryg) and ethyl eicosapentaenoic<unk> (Vascepa), to be approved for use as a drug. The first approval by US Food and Drug Administration was granted 05 May 2014. These fish oil drugs are similar to fish oil dietary supplements, but the ingredients are better controlled and have been tested in clinical trials. Specifically, Epanova contained at least 850 mg omega-3-acid ethyl esters per 1 g capsule. Following phase III clinical trial in mixed dyslipidaemia, AstraZeneca announced on 13 January 2019 that their clinical trials were terminated for futility because no medical benefit of the medication could be found.
Omega-3 carboxylic acids
Omega-3 fatty acid
Omega-3 acid ethyl esters
Fish oil 
Fish oil
Omega-6 fatty acid
Dietary fiber
Cholic acid